20
Participants
Start Date
January 15, 2019
Primary Completion Date
April 30, 2022
Study Completion Date
October 31, 2022
KRT-232
KRT-232, administered by mouth
Ruxolitinib
Ruxolitinib per approved prescribing label
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Gyula
Hospital Universitario Virgen de la Victoria, Málaga
The Kirklin Clinic of UAB Hospital, Birmingham
Hospital Universitario de Salamanca, Salamanca
The Ohio State University Comprehensive Cancer Center, Columbus
Gabrail Cancer Center, Canton
Washington University School of Medicine, St Louis
Stauferklinikum Schwäbisch Gmünd, Mutlangen
University of Southern California Norris Comprehensive Cancer Center, Los Angeles
Center Hospitalier Universitaire d'Angers, Angers
Universitätsklinikum Aachen, Aachen
Gemeinschaftspraxis Haematologie - Onkologie - Hauptstelle, Dresden
Universitätsklinikum Carl Gustav Carus, Dresden
Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku, Wroclaw
Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria
Szpital Wojewódzki w Opolu, Opole
Lead Sponsor
Kartos Therapeutics, Inc.
INDUSTRY